Short Interest in GeoVax Labs, Inc. (NASDAQ:GOVX) Expands By 17.2%

GeoVax Labs, Inc. (NASDAQ:GOVX) was the target of a large growth in short interest in September. As of September 30th, there was short interest totalling 301,200 shares, a growth of 17.2% from the September 15th total of 256,900 shares. Based on an average daily trading volume, of 4,630,000 shares, the days-to-cover ratio is presently 0.1 days.

Analyst Upgrades and Downgrades

Several analysts recently weighed in on the company. Noble Financial lifted their price objective on GeoVax Labs from $6.00 to $10.00 and gave the company an “outperform” rating in a report on Monday, August 19th. EF Hutton Acquisition Co. I upgraded shares of GeoVax Labs to a “strong-buy” rating in a report on Tuesday, July 23rd. Roth Mkm initiated coverage on shares of GeoVax Labs in a research note on Tuesday, July 16th. They set a “buy” rating and a $20.00 price objective on the stock. Roth Capital raised shares of GeoVax Labs to a “strong-buy” rating in a report on Tuesday, July 16th. Finally, HC Wainwright restated a “buy” rating and set a $8.00 target price on shares of GeoVax Labs in a report on Monday, August 12th. Three analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and a consensus target price of $12.67.

GeoVax Labs Stock Performance

Shares of GOVX stock traded down $0.01 during mid-day trading on Wednesday, hitting $2.10. 350,358 shares of the stock traded hands, compared to its average volume of 2,426,837. GeoVax Labs has a 52-week low of $1.09 and a 52-week high of $11.18. The stock’s fifty day moving average is $3.49 and its two-hundred day moving average is $2.54.

GeoVax Labs (NASDAQ:GOVX) last posted its earnings results on Tuesday, August 6th. The company reported ($1.99) EPS for the quarter, beating analysts’ consensus estimates of ($2.57) by $0.58. The firm had revenue of $0.30 million for the quarter. During the same period last year, the firm earned ($3.30) earnings per share. On average, equities analysts forecast that GeoVax Labs will post -5.1 EPS for the current fiscal year.

GeoVax Labs Company Profile

GeoVax Labs, Inc, a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using modified vaccinia ankara virus-like particle vaccine platform. It is developing various preventive vaccines against (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for HIV, chronic Hepatitis B infections, and solid tumor cancers.